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Asthma is an important cause of chronic mor-
bidity and a crucial health problem among
children and adults worldwide, with high
prevalence rates particularly in many devel-
oped countries.1 2 Increasing morbidity, hospi-
tal admission rates, use of medical services,
drug use and, in some countries, increasing
mortality rates have been reported.3 However,
controversy still exists regarding the epidemiol-
ogy of asthma. There are two serious problems
which need to be considered when trying to
obtain reliable data on the prevalence, morbid-
ity, and mortality of asthma. The first relates to
definition; despite substantial advances in
understanding the pathogenesis, genetics, and
clinical characteristics of asthma, we do not
have a useful definition of asthma for epide-
miological purposes.2 The second problem
concerns the diVerent methods used to collect
epidemiological data and information. More
recently two international studies—the Euro-
pean Community Respiratory Health Survey
(ECRHS)4 and the International Study of
Asthma and Allergies in Childhood
(ISAAC)5—have used the same internationally
standardised questionnaire to provide impor-
tant data on the prevalence of asthma.
In the ISAAC study the prevalence of symp-
toms in 13–14 years old subjects was highly
variable (from 1.6% to 36.8% in diVerent
countries). The higher prevalence was in the
UK, New Zealand, and Australia while the
prevalence of asthma in eastern Europe,
Greece, and China was considerably lower. In
the ECRHS study, performed in a large cohort
of 20–44 year old subjects, the prevalence of
asthma was higher in the UK, New Zealand,
and the USA and lower in central and southern
European countries. These data show a link
between the prevalence of asthma and the geo-
graphical area or distribution of risk factors.
Although the ECRHS and ISAAC studies may
help to identify specific risk factors for current
asthma, neither study has answered questions
on changes in prevalence or severity of asthma
over time, unless subsequent studies with the
same methodology are undertaken in future
years.
However, there have been a number of
epidemiological studies repeated in the same
population with similar methods which suggest
that asthma prevalence and severity have
increased.6 7 In Aberdeen essentially identical
studies were undertaken in children 25 years
apart.6 In 1989 the prevalence of asthma had
doubled from the figure in 1964. The preva-
lence of eczema and hay fever had also
increased, which suggests that the increase in
asthma related primarily to an increase in the
prevalence of allergy.
Among 12 year old children in South Wales,
the prevalence of a history of wheezing at any
time increased from 17% in 1973 to 22% in
1988, and a history of asthma from 6% to 12%.
The prevalence rates for eczema and hay fever
also rose over the 15 year period.7
Reasons for the increased prevalence of
asthma or increased allergy may include a
greater proliferation of house dust mites,
increasing both sensitisation and exposure, or
eVects of outdoor and indoor environmental
factors such as passive smoking.8 The impact of
early childhood infections and the subsequent
immunological shift from Th1 to Th2 is
currently of major interest.
During the 1970s and 1980s asthma mor-
tality increased among young people in many
countries.2 3 Revisions in coding of airway dis-
eases according to the International Classifi-
cation of Diseases could have determined a
mismatch in interpretation of death from
“bronchitis or asthma”, especially in older
people. However, the revision of the codes had
a minimal impact in 5–34 year old subjects and
in many countries asthma mortality in this age
group increased from the mid 1970s to the
second half of the 1980s. Evidence from the
two epidemics of asthma mortality in young
people suggests that mortality increased with
the introduction of high dose formulations of
inhaled â agonists.9
As asthma is such a common illness, its eco-
nomic impact is a heavy burden on health care
resources.10 The estimated costs of asthma—
usually divided into direct, indirect, and intan-
gible costs—are very high. Direct costs are
those associated with drugs and devices, physi-
cians, and hospitals. Indirect costs are defined
as “lost resources” such as time oV work and
school, and premature retirement. Intangible
costs are related to quality of life impairment
and social problems of the patients and their
families.11 It is a common shared concept that
good management of the disease could lead to
decreasing morbidity, mortality, and costs of
asthma.3
As with all chronic diseases, the responsibil-
ity for the daily management needs to be
shared between health care professionals,
patients, and their families.3 Moreover, asthma
is a chronic disease that varies greatly in time
with long symptom free periods, and patients
can find it diYcult to perceive and accept that
the disease is a chronic one. The increase in
morbidity and mortality is also related to the
poor adherence to long term anti-
inflammatory treatment. In fact, incorrect
asthma management (such as misuse or over-
use of drugs, poor perception of symptoms,
prolonged exposure to exacerbating factors)
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can be life threatening and can explain, at least
in part, excess mortality and morbidity.12
EVorts to increase compliance with treatment
and a good relationship between patient and
doctor are needed to obtain good long term
asthma management. Teaching asthmatic pa-
tients about their illness is strongly recom-
mended in international guidelines on asthma
management3; the aims are to provide knowl-
edge, capacity, motivation, and self-confidence
to control the illness. There is evidence that
educating patients and their families can
achieve not only an increase in knowledge, but
also a reduction in morbidity, mortality and
related costs, and an improvement in the
quality of life.13 14
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